Diabetes Management Tablet in pharma franchise in Tripura

Diabetes Management Tablet in PCD pharma franchise in Patna

Diabetes Management Tablet in top pharma company in Nagpur

Diabetes Management Tablet in pcd pharma supplier in Indore

Diabetes Management Tablet in phama franchise company in India
Diabetes Management Tablet in phama distributor in Thane

Home/Products /empagliflozin-25mg-sitagliptin-100mg-metformin-1000mg-extended-release-tablet

About the Product

Description


Emplozin SM 25 Tablet is a combination therapy for the treatment of Type 2 diabetes mellitus in adults. It contains three active ingredients: Empagliflozin, Sitagliptin, and Metformin, each targeting different aspects of glucose regulation to help manage blood sugar levels effectively. This tablet is designed for patients who are not adequately controlled on diet, exercise, or other medications alone.

  • Empagliflozin (25mg) is an SGLT2 inhibitor, which reduces the reabsorption of glucose by the kidneys, allowing more glucose to be excreted in the urine, thus lowering blood sugar levels.
  • Sitagliptin (100mg) is a DPP-4 inhibitor that helps increase insulin production in response to meals and reduces glucose production by the liver.
  • Metformin (1000mg) is a biguanide that helps lower blood sugar by reducing liver glucose production and improving insulin sensitivity. The extended-release formulation minimizes gastrointestinal side effects while offering sustained glucose control throughout the day.

Together, these medications work synergistically to improve glycemic control, both in fasting and postprandial states. Emplozin SM 25 Tablet is recommended for patients with Type 2 diabetes who have not achieved optimal blood glucose levels through diet, exercise, and other oral medications. This combination helps manage blood sugar levels and reduces the risk of complications related to diabetes.

Possible side effects include nausea, headache, abdominal pain, dizziness, and risk of low blood sugar (especially when used with other anti-diabetic medications). Severe effects may include lactic acidosis or kidney problems.

For the treatment of Type 2 diabetes mellitus in adults to improve blood glucose control, alongside diet and exercise.

Not recommended for patients with severe kidney disease or diabetic ketoacidosis. Kidney function should be monitored regularly during treatment.

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Empagliflozin 25mg + Sitagliptin 100mg + Metformin 1000mg ER Tablet in the PCD pharma franchise market?

This advanced triple-combination anti-diabetic formulation is widely used in type 2 diabetes management, making it a high-value prescription product for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma pharma franchise market.

Why should medical distributors include this tablet in their product range?

Medical distributors and wholesalers can benefit from strong demand in type 2 diabetes, blood sugar control, insulin resistance management, cardiovascular risk reduction support, and long-term glycemic control. The extended-release formulation improves patient compliance and is commonly prescribed by diabetologists and physicians for multi-drug diabetes management.

Does Cafoli Lifecare offer PCD pharma franchise opportunities for this product?

Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities for Empagliflozin 25mg + Sitagliptin 100mg + Metformin 1000mg Extended Release Tablets with monopoly rights, quality packaging, competitive pricing, and reliable supply support for distributors and medical agencies.

What benefits do wholesalers get by partnering for this anti-diabetic product?

Wholesalers and medical agencies benefit from strong chronic prescription demand, growing diabetic patient populations, repeat monthly therapy usage, and high acceptance in diabetology and general medicine segments when partnering with Cafoli Lifecare.

How can I become a distributor or franchise partner for this tablet?

Medical distributors, stockists, wholesalers, and pharma professionals interested in this anti-diabetic formulation can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, pricing, and distribution support services.